Vitrolife appoints Elin Frostehav as new CEO

In May, Vitrolife announced that Bronwyn Brophy O'Connor had decided to step down as President and CEO to take up the same role at German medtech company Carl Zeiss Meditec. Vitrolife has now confirmed that Elin Frostehav will succeed her, taking up the position no later than 1 May 2027.

Elin Frostehav is currently President of Acute Care Therapies at Getinge and a member of the company's executive management team, a position she has held since 2022. She has previously held global roles in product development and digitalisation at Semcon and FlexLink. She holds a Master of Science degree in Industrial Engineering and Management from Linköping University.

“After a career in medical technology, most recently in critical care, I am joining a company with a strong position, a clear strategy and a team that makes a real difference for clinics and patients,” Elin Frostehav said in a press statement.

Bronwyn Brophy O'Connor will leave Vitrolife on 1 November, with Rickard Ericsson, Senior Vice President of Innovation at Vitrolife Group, serving as interim CEO until Elin Frostehav takes up the position.

The announcement means that Getinge is losing two business area heads in quick succession. Earlier in October, the company announced that Eric Honroth would step down as President of Life Science to become CEO of AngioDynamics.